• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

PROTECT CAP Continuation PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Study Pending
Application Number P200031 / PAS002
Date Current Protocol Accepted  
Study Name PROTECT CAP Continuation PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source External Registry
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent A (distinctively) : 18-21 yrs, Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This single-arm study is a continued follow-up of the OCS Liver PROTECT Continued Access Protocol (CAP) cohort (premarket), designed to evaluate longer-term outcomes after transplantation with OCS-perfused livers



Study Population Description Patients who were transplanted in the OCS Liver PROTECT CAP study



Sample Size 74 patients who were transplanted in the PROTECT CAP study



Data Collection Main effectiveness endpoint: Liver graft survival at 24 months post-transplant



Other endpoint: patient survival at 24 months post-transplant



Follow-up Visits and Length of Follow-up 2 years


PROTECT CAP Continuation PAS Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 03/28/2022    
1 year report 09/28/2022    
18 month report 03/28/2023    
final report 06/30/2023    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-